RxDoctor Payments Data

Enrico Belgrave, MD

Internal Medicine · Charlotte, NCNPI 1518982586

Payments from drug & device makers

$1,803in general payments, 2019–2025

Across 101 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$610
  • AbbVie$259
  • Pfizer$168
  • GSK$166
  • Abbott$156
  • Sanofi-aventis U.S. LLC$106
  • plus $339 from 11 others

What the payments were for

  • Food & beverage$1,803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,803 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$121,610
Medicare patients
254
Services billed
2,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$123,978
EliquisApixaban84$73,887
XareltoRivaroxaban37$26,170
JardianceEmpagliflozin31$24,103
FarxigaDapagliflozin Propanediol34$23,579
MounjaroTirzepatide16$16,766
LinzessLinaclotide15$12,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,960
Janumet XrSitagliptin Phos/Metformin Hcl12$6,742
TradjentaLinagliptin11$5,680
SynthroidLevothyroxine Sodium56$5,575
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,508
Atorvastatin Calcium386$2,585
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,355
Levothyroxine Sodium261$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$610$123,97894 claims
PfizerEliquis, Paxlovid$168$75,31698 claims
AstraZenecaFarxiga$11$23,57934 claims
AbbVieLinzess, Synthroid$259$17,64671 claims
Lilly USA, LLCMounjaro$13$16,76616 claims
GSKTrelegy Ellipta, Shingrix$166$12,46730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →